Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

The efficacy and safety of apixaban for VTE prophylaxis in major orthopedic surgery have been evaluated in one Phase II trial and three Phase III trials. Traditional treatment of acute VTE entails ...

Bayer and Janssen’s novel oral anticoagulant (NOAC ... is playing catch-up with Bristol-Myers Squibb’s Eliquis (apixaban) in the competitive market for NOACs, where Boehringer Ingelheim ...

The research team focused the study on the two most prescribed direct oral anticoagulants, or DOACs, rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis). Investigators analyzed ...

it is the leading novel oral anticoagulant (NOAC). According to various industry reports, apixaban was the second-highest-selling drug globally in 2023. About TAHO Pharmaceuticals Ltd. Founded in ...

With notable safety advantages, it is the leading novel oral anticoagulant (NOAC). According to various industry reports, apixaban was the second-highest-selling drug globally in 2023. About TAHO ...

TAIPEI, Jan. 21, 2025 /CNW/ -- TAHO Pharmaceuticals is pleased to announce the successful completion of the pivotal trial for TAH3311, the first anticoagulant oral dissolving film (ODF).